KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Change in Receivables: 2020-2025

Historic Change in Receivables for Esperion Therapeutics (ESPR) over the last 5 years, with Sep 2025 value amounting to $11.2 million.

  • Esperion Therapeutics' Change in Receivables rose 50.51% to $11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.2 million, marking a year-over-year increase of 102.99%. This contributed to the annual value of $31.6 million for FY2024, which is 114.34% up from last year.
  • Per Esperion Therapeutics' latest filing, its Change in Receivables stood at $11.2 million for Q3 2025, which was down 57.53% from $26.5 million recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Change in Receivables registered a high of $26.5 million during Q2 2025, and its lowest value of -$144,000 during Q3 2021.
  • For the 3-year period, Esperion Therapeutics' Change in Receivables averaged around $7.8 million, with its median value being $5.9 million (2023).
  • Per our database at Business Quant, Esperion Therapeutics' Change in Receivables slumped by 105.01% in 2021 and then surged by 2,631.25% in 2022.
  • Esperion Therapeutics' Change in Receivables (Quarterly) stood at $1.2 million in 2021, then soared by 83.01% to $2.2 million in 2022, then spiked by 162.10% to $5.9 million in 2023, then spiked by 109.81% to $12.3 million in 2024, then spiked by 50.51% to $11.2 million in 2025.
  • Its last three reported values are $11.2 million in Q3 2025, $26.5 million for Q2 2025, and $1.2 million during Q1 2025.